NCT01238393CompletedNot Applicable
A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Queen's University
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Evidence of improvement measured by optical coherence tomography
Study Overview
Brief Summary
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •symptomatic idiopathic epiretinal membrane
Exclusion Criteria
- •vision worse than 6/18 and fit for surgery
- •prior vitreoretinal surgery or injection
- •any past or current form of retinal vein occlusion or neovascularization
- •age-related macular degeneration
- •other condition causing significant limitation of visual potential
Arms & Interventions
Ranibizumab
Experimental
('intravitreal ranibizumab' )
Intervention: intravitreal ranibizumab (Drug)
Outcomes
Primary Outcomes
Evidence of improvement measured by optical coherence tomography
Time Frame: 3 and 6 months
Secondary Outcomes
- Subjective change in symptoms(3 and 6 months)
- Amsler grid improvement(3 and 6 months)
- Near visual acuity (Snellen)(3 and 6 months)
- Distance visual acuity (ETDRS)(3 and 6 months)
- Quality of life improvement(6 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel GrowthNeovascularizationNCT00685503National Eye Institute (NEI)1
Completed
Phase 1
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel GrowthMacular TelangiectasiaNCT00685854National Eye Institute (NEI)5
Completed
Phase 2
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)Proliferative Diabetic RetinopathyVitreous HemorrhageNCT00996437Jaeb Center for Health Research261
Completed
Phase 1
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel FormationTelangiectasiaNCT00457145National Eye Institute (NEI)5
Completed
Phase 1
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel FormationTelangiectasiaNCT00457067National Eye Institute (NEI)5